Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company.
Flawless balance sheet and fair value.
Share Price & News
How has Concert Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 73C's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 73C underperformed the German Biotechs industry which returned -13.2% over the past year.
Return vs Market: 73C underperformed the German Market which returned -20.9% over the past year.
Price Volatility Vs. Market
How volatile is Concert Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Concert Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 73C (€7) is trading below our estimate of fair value (€42.06)
Significantly Below Fair Value: 73C is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 73C is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 73C is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 73C's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 73C is good value based on its PB Ratio (1.9x) compared to the DE Biotechs industry average (3.3x).
How is Concert Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 73C is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 73C is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 73C is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 73C's revenue (59.8% per year) is forecast to grow faster than the German market (3.9% per year).
High Growth Revenue: 73C's revenue (59.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 73C's Return on Equity is forecast to be high in 3 years time
How has Concert Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 73C is currently unprofitable.
Growing Profit Margin: 73C is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 73C is unprofitable, and losses have increased over the past 5 years at a rate of -15.1% per year.
Accelerating Growth: Unable to compare 73C's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 73C is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: 73C has a negative Return on Equity (-77.04%), as it is currently unprofitable.
How is Concert Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: 73C's short term assets ($116.9M) exceed its short term liabilities ($17.3M).
Long Term Liabilities: 73C's short term assets ($116.9M) exceed its long term liabilities ($18.7M).
Debt to Equity History and Analysis
Debt Level: 73C is debt free.
Reducing Debt: 73C has no debt compared to 5 years ago when its debt to equity ratio was 12.8%.
Inventory Level: 73C has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 73C's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 73C has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 73C has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -2.5% each year.
What is Concert Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 73C's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 73C's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 73C's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 73C's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 73C's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Roger Tung (59yo)
Dr. Roger D. Tung, Ph.D., Co-founded Concert Pharmaceuticals, Inc. in April 2006 and has been its Chief Executive Officer and President since April 2006. Dr. Tung worked in venture-backed start-up and majo ...
CEO Compensation Analysis
Compensation vs Market: Roger's total compensation ($USD4.61M) is above average for companies of similar size in the German market ($USD744.69K).
Compensation vs Earnings: Roger's compensation has increased whilst the company is unprofitable.
|Co-Founder & Chairman of the Board||13.92yrs||US$205.61k||1.3% $2.8m|
|Chief Financial Officer||2.25yrs||US$2.45m||no data|
|Chief Operating Officer||12.5yrs||US$1.91m||0.34% $735.4k|
|Senior Vice President of Corporate Communications and Investor Relations||no data||no data||no data|
|Chief Legal Officer & Corporate Secretary||0.58yr||no data||no data|
|Chief Development Officer||5.17yrs||US$1.96m||0.072% $153.6k|
|Senior Legal Advisor||2.83yrs||US$539.56k||no data|
Experienced Management: 73C's management team is considered experienced (4 years average tenure).
|Co-Founder & Chairman of the Board||13.92yrs||US$205.61k||1.3% $2.8m|
|Independent Director||4yrs||US$181.25k||0.034% $72.6k|
|Independent Director||12.33yrs||US$185.12k||no data|
|Independent Director||13.33yrs||US$181.32k||0.015% $32.1k|
|Independent Director||13.92yrs||US$181.25k||no data|
|Director||1yr||no data||no data|
|Independent Director||5.33yrs||US$188.75k||0.022% $47.2k|
Experienced Board: 73C's board of directors are seasoned and experienced ( 12.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 73C insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Concert Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Concert Pharmaceuticals, Inc.
- Ticker: 73C
- Exchange: DB
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$230.492m
- Listing Market Cap: US$213.643m
- Shares outstanding: 29.44m
- Website: https://www.concertpharma.com
Number of Employees
- Concert Pharmaceuticals, Inc.
- 65 Hayden Avenue
- Suite 3000N
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CNCE||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Feb 2014|
|73C||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2014|
|73C||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||Feb 2014|
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer’s disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/05 05:12|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.